![](/wp-content/uploads/2024/06/Screenshot-2024-06-03-at-4.50.26%E2%80%AFPM.png)
$599
Novo Launches New Wegovy Campaign; Structure Reports Positive GSBR-1290 Topline Obesity Data
Two cardiometabolic-related news items have been observed: Novo Nordisk launched a campaign for Wegovy called “Power of Wegovy” highlighting Wegovy 2.4mg clinical data which includes CV risk reduction based on SELECT (view press release); and Structure Therapeutics reported positive topline data from its Ph2a GSBR-1290 obesity trial and its capsule to tablet PK study (view press release). Below, FENIX provides highlights and insights for the respective news items.